BioAge Labs has reported promising interim Phase 1 data for its oral NLRP3 inhibitor, BGE-102, which demonstrates significant reductions in inflammatory biomarkers associated with cardiovascular risk. CEO Kristen Fortney highlighted that the data indicate BGE-102 could provide injectable-like anti-inflammatory effects in a convenient oral format. The company plans to initiate a Phase 2a proof-of-concept study in cardiovascular risk in the first half of 2026, with full Phase 1 data expected soon.

This development is particularly relevant to the longevity and healthspan research community, as it underscores a growing trend toward targeting inflammation—a key driver of aging-related diseases. The Phase 1 results show an impressive 86% median reduction in high-sensitivity C-reactive protein (hsCRP) among participants with obesity, alongside reductions in IL-6 and fibrinogen. These findings suggest that BGE-102 may not only mitigate cardiovascular risks but also have therapeutic potential across various conditions, including diabetic macular edema, as BioAge expands its application of this compound into ophthalmology.

A key takeaway for professionals in the field is the strategic expansion of BGE-102’s indications, which could position it as a versatile therapeutic agent across multiple disease states linked to aging. The company’s robust financial backing, with over $132 million raised, further supports its ambitious clinical development plans. As BioAge continues to explore the intersection of aging biology and therapeutic innovation, its progress may catalyze new approaches to managing age-related inflammatory diseases.

Source: lifespan.io